

Pharmaceutical Policies Updates Effective April 1, 2022

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes** – Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective April 1, 2022 and will be available for viewing on or before March 1, 2022. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Phenylketonuria Agents	Updated
Infertility Drug Therapy (Commercial/Marketplace)	Updated
Infertility Drug Therapy (Medicaid/HARP)	Updated
Hepatitis C Treatment Commercial, Marketplace, Child Health Plus	Updated
Hepatitis C Treatment Medicaid	Updated
Pharmacy Management Programs	Updated
Prescribers Treating Self or Family Members	Updated
Multiple Sclerosis Agents	Updated
Government Programs Over-the-Counter (OTC) Drug Coverage (For MVP Medicaid, Child Health Plus and select Essential Plan Members Only) – EFFECTIVE 02/01/2022	Updated
Spravato – EFFECTIVE 12/23/2021	Updated
Select Injectables for Asthma	Updated
Male hypogonadism	Reviewed/No Changes
Transgender Hormone Therapy (Medicaid/HARP)	Reviewed/No Changes
Transgender Hormone Therapy (COMM/EXCH/CHP)	Reviewed/No Changes
Metformin ER	Reviewed/No Changes
Jynarque	Reviewed/No Changes
Acthar	Reviewed/No Changes
Physician Prescription Eligibility	Reviewed/No Changes
Mail Order	Reviewed/No Changes

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

